This site is intended for health professionals only

Lung infection represented by a human with x-ray image of the lungs and body with virus cells attacking the patient to a state of dangerous respiratory illness.
Published on 22 May 2007

Share this story:

Oral vs IV topotecan: little difference

teaser

In this open-label phase III study, researchers compared the safetyand efficacy of oral and IV topotecan in patients with small-cell lungcancer (SCLC) sensitive to initial chemotherapy.

A total of309 adults with limited or extensive-stage SCLC who had documentedcomplete or partial response (CR or PR) to first-line therapy withdisease recurrence after at least 90 days were randomised to oral(2.3mg/m2/day; n=153) or IV (1.5 mg/m2/day; n=151) topotecan on days 1to 5, every three weeks. Patients who responded to treatment (CR/PR)continued treatment until disease progression, or for two coursesbeyond best response. Primary endpoint was response rate; secondaryendpoints included duration of response, time to progression, time toresponse, survival, quality of life and toxicity.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Therapy wascompleted by 81% of the oral and 85% of the IV group. Inintent-to-treat analysis, response rates were similar for oral and IVtopotecan (18.3% vs 21.9%; difference of -3.6% 95%CI, -12.6–5.5%).Median survival times were also similar (33 and 35 weeks respectively;hazard ratio 0.98; 95% CI 0.77–1.2), as was median time to response(6.1 vs 6.1 weeks), median duration of response (18.3 vs 25.4 weeks)and median time to progression (11.9 vs 14.6 weeks).

Adverseeffects caused 12% of patients assigned to oral topotecan and 13% ofthose assigned to IV treatment to withdraw from therapy. Incidence ofgrade 4 toxicity in patients receiving oral and IV topotecan,respectively, was as follows: neutropenia in 47% and 64%,thrombocytopenia in 29% and 18%, grade 3 or 4 anaemia in 23% and 31%,and sepsis in 3%. The most frequent nonhaematological adverse events(all grades) included nausea (43% oral; 42% IV), alopecia (26% oral;30% IV), fatigue (31% oral; 36% IV) and diarrhoea (36% oral; 20% IV).

J Clin Oncol 2007;25(15):2086-92

 






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x